Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

E-ISSN： 1873-4286|22|16|2349-2357

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.16, 2016-05, pp. : 2349-2357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

Current Cancer Drug Targets, Vol. 11, Iss. 7, 2011-09 ,pp. : 837-848

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes

By Gotlib Jason Greenberg Peter L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 473-480

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Lenalidomide for Treatment of Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of Age and Comorbidity in Myelodysplastic Syndromes

By Stauder Reinhard Nösslinger Thomas Pfeilstöcker Michael Sperr Wolfgang R. Wimazal Friedrich Krieger Otto Valent Peter

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 9, 2008-10 ,pp. : 927-934

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz Keane Niamh Freeman Ciara Louise Swords Ronan O'Dwyer Michael Giles Francis J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite